Literature DB >> 16225526

The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).

Remigio Vela-Navarrete1, Carmen Gonzalez-Enguita, Juan V Garcia-Cardoso, Felix Manzarbeitia, Jose Luis Sarasa-Corral, Juan José Granizo.   

Abstract

OBJECTIVES: To compare the clinical profile (age, comorbidities, symptom severity, and incidence of acute urinary retention, AUR), the type and duration of medical treatment, and indications for surgery of patients undergoing surgery for benign prostatic hyperplasia (BPH) in 1992 and 2002 at one centre. PATIENTS AND METHODS: In this single-centre, retrospective, cross-sectional observational study, the medical history of all patients who had surgery for BPH in the first semester of 1992 (85) and 2002 (70) was reviewed. The preoperative clinical profile was determined by assessing age, main comorbidities, prostatic volume, maximum urinary flow rate and symptom severity. The type and duration of pharmacology for BPH was evaluated from the medical history and telephone contact with the patients. Indications for surgery, the method of operation and the weight of removed tissue (open adenectomy) or the volume of the resected tissue (transurethral resection) were obtained from the patients' records and compared. Surgical complications in both groups were assessed, as was the average stay in hospital.
RESULTS: In our institution, surgery for BPH decreased by 17.6% in the decade, with patients having surgery when older, at a mean (sd) of 69.1 (8.57) vs 72.3 (7.59) years, i.e. 3.1 years older (P = 0.028), but with similar comorbidities. Reasons for surgery in 1992/2002, respectively, were AUR in 41/37%, and symptoms worsening in 48/51%. The few cases of haematuria and bladder stone were similarly distributed in both groups. Pharmacology for BPH was prescribed in 46% of patients in 1992, phytotherapy being the most common (89%), whereas in 2002, 82% (P < 0.01) were treated, most of them with alpha-adrenergic antagonists (79%). Open surgery was indicated in 18.8% of patients in 1992 (mean adenoma weight 73.8 g, sd 37.12) and in 28.6% in 2002 (79.8 g, sd 35.41; P = 0.625). The mean (sd) hospital stay was 8.9 (4.06) vs 5.0 (1.22) days in 1992 and 2002, respectively (P < 0.01) for transurethral resection, and 14.1 (5.74) vs 8.7 (4.83) for open adenectomy (P = 0.013). The complication rate was similar for both groups.
CONCLUSIONS: Compared with 1992, fewer patients with BPH have surgery, when older and after receiving medical treatment for longer. The indications for surgery are similar. Significantly more patients had open surgery, perhaps because the progressive increase in prostate volume was not affected by the medical therapy used predominantly during this decade.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225526     DOI: 10.1111/j.1464-410X.2005.05735.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

1.  Extraperitoneal laparoscopic adenomectomy for benign prostatic hyperplasia.

Authors:  Lin-Yu Zhou; Jun Xiao; Hao Chen; Yu-Ping Zhu; You-Wen Sun; Qiang Xuan
Journal:  World J Urol       Date:  2008-12-10       Impact factor: 4.226

Review 2.  Can Long-term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention?

Authors:  Fabrizio Presicce; Cosimo De Nunzio; Andrea Tubaro
Journal:  Curr Urol Rep       Date:  2017-09       Impact factor: 3.092

3.  Management of urinary incontinence.

Authors:  George A Demaagd; Timothy C Davenport
Journal:  P T       Date:  2012-06

4.  Changing patients' profile presenting for surgical management of benign prostatic hyperplasia over the past 16 years: A single-centre perspective.

Authors:  Mohamed A Elkoushy; Ahmed M Elshal; Mostafa M Elhilali
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

Review 5.  Clinical Implications for the Early Treatment of Benign Prostatic Enlargement (BPE): a Systematic Review.

Authors:  Fabrizio Presicce; Cosimo De Nunzio; Andrea Tubaro
Journal:  Curr Urol Rep       Date:  2018-07-09       Impact factor: 3.092

Review 6.  Dutasteride: a review of its use in the management of prostate disorders.

Authors:  Susan J Keam; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Impact of changing trends in medical therapy on surgery for benign prostatic hyperplasia over two decades.

Authors:  Se Young Choi; Tae-Hyoung Kim; Soon Chul Myung; Young Tae Moon; Kyung Do Kim; Young Sun Kim; Hye-Ryoun Kim; In Ho Chang
Journal:  Korean J Urol       Date:  2012-01-25

8.  Thermo-expandable prostatic stents for bladder outlet obstruction in the frail and elderly population: An underutilized procedure?

Authors:  Kapil Sethi; Michael Bozin; Tebogo Jabane; Richard McMullin; David Cook; Rob Forsyth; Lachlan Dodds; Lydia Johns Putra
Journal:  Investig Clin Urol       Date:  2017-10-23

Review 9.  The evolution of KTP laser vaporization of the prostate.

Authors:  Petros Sountoulides; Peter Tsakiris
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759

Review 10.  The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.

Authors:  Eric H Kim; John A Brockman; Gerald L Andriole
Journal:  Asian J Urol       Date:  2017-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.